In the latest trading session, 1.56 million Bristol-Myers Squibb Co (NYSE:BMY) shares changed hands as the company’s beta touched 0.42. With the company’s most recent per share price at $60.18 changing hands around $0.28 or 0.47% at last look, the market valuation stands at $122.13B. BMY’s current price is a discount, trading about -5.23% off its 52-week high of $63.33. The share price had its 52-week low at $39.35, which suggests the last value was 34.61% up since then. When we look at Bristol-Myers Squibb Co’s average trading volume, we note the 10-day average is 12.52 million shares, with the 3-month average coming to 11.64 million.
Analysts gave the Bristol-Myers Squibb Co (BMY) stock a consensus recommendation rating of Hold, calculated at a mean rating of 2.56. If we narrow down to specifics, the data shows that 0 out of 14 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 9 recommended BMY as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Bristol-Myers Squibb Co’s EPS for the current quarter is expected to be 1.54.
Bristol-Myers Squibb Co (NYSE:BMY) trade information
Instantly BMY is in green as seen in intraday trades today. With action 0.62%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 6.40%, with the 5-day performance at 0.62% in the green. However, in the 30-day time frame, Bristol-Myers Squibb Co (NYSE:BMY) is 10.57% up. Looking at the short shares, we see there were 30.57 million shares sold at short interest cover period of 2.54 days.
The consensus price target for the stock as assigned by Wall Street analysts is 61, meaning bulls need an upside of 1.34% from its recent market value. According to analyst projections, BMY’s forecast low is 61 with 61 as the target high. To hit the forecast high, the stock’s price needs a -1.36% plunge from its current level, while the stock would need to soar -1.36% for it to hit the projected low.
Bristol-Myers Squibb Co (BMY) estimates and forecasts
Year-over-year growth is forecast to reach -5.36% down from the last financial year.
Consensus estimates given by 15 financial analysts project the company’s revenue in the current quarter to hit an average of 10.77B. 14 analysts are of the opinion that Bristol-Myers Squibb Co’s revenue for the current quarter will be 11.3B. The company’s revenue for the corresponding quarters a year ago was 11.87B and 12.2B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -9.23%. The estimates for the next quarter sales put growth at -7.35%.
The 2025 estimates are for Bristol-Myers Squibb Co earnings to increase by 486.00%, but the outlook for the next 5-year period is at 73.71% per year.
BMY Dividends
Bristol-Myers Squibb Co is expected to release its next quarterly earnings report on 2025-Feb-05. The 4.02% annual yield figure for the share gives it an annual dividend of 2.42. It is important to note, however, that the 4.02% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision. During the past 5 years, the average dividend yield was 3.5 per year.
Bristol-Myers Squibb Co (NYSE:BMY)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.10% of Bristol-Myers Squibb Co shares while 80.81% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 80.88%. There are 80.81% institutions holding the Bristol-Myers Squibb Co stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 9.2225% of the shares, roughly 186.57 million BMY shares worth $7.75 billion.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.8428% or 158.66 million shares worth $6.59 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. With 63.59 shares estimated at $3.81 billion under it, the former controlled 3.13% of total outstanding shares. On the other hand, Vanguard 500 Index Fund held about 2.71% of the shares, roughly 54.9 shares worth around $3.29 billion.
